ARTEMIS and Taconic Acquire Chemical Genetics Technology From CGI Pharmaceuticals, Inc.
Taconic Farms, Inc. and ARTEMIS Pharmaceuticals GmbH announced that they have jointly acquired the worldwide rights to the ASKA technology from CGI Pharmaceuticals Inc. ASKA technology is based on the replacement of a normal kinase with a selectively modified kinase or "ASKA" (Analogue Sensitive Kinase Allele) in genetically modified mice.
Under the terms of the transaction, ARTEMIS and Taconic are assigned the entire portfolio of ASKA intellectual property rights (including all ASKA IP that CGI had previously licensed exclusively from Princeton University) as well as know-how, trade secrets and materials developed by CGI. Included are the rights to patents based on the chemistry and molecular biology work of Dr. Kevan Shokat, inventor of the ASKA technology. Financial details of the transaction were not disclosed.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.